Stay updated with breaking news from Regeneronv mylan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On Friday, January 20, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") filed an ex parte application for a scheduling order setting the schedule for preliminary injunction proceedings or, in the alternative, an emergency status conference. ....
As previously reported by Big Molecule Watch, trial in Regeneron's BPCIA case against Biocon regarding Biocon's proposed aflibercept biosimilar concluded on June 15, 2023 in the Northern District of West Virginia. ....
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide. ....